Advertisement


Saad Z. Usmani, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.



Related Videos

COVID-19
Global Cancer Care
Skin Cancer

Paolo A. Ascierto, MD, on Cancer Treatment During the COVID-19 Pandemic: The View From Southern Italy

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori in Naples, Italy, talks about minimizing risks for patients with cancer, prioritizing surgery and other treatments for melanoma, and the state of clinical trials. Filmed April 17, 2020.

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19

Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, discusses the concerns his patients with cancer have about exposure to COVID-19 when they come to his institution for care and how he manages their fears. Filmed April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 1

Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma?

Recorded April 21, 2020.

Hematologic Malignancies
COVID-19

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 3

Advertisement

Advertisement




Advertisement